Vaxxinity, Inc. stock is down -34.6% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November.
Vaxxinity, Inc. focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company is developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial. It is also developing an anti-tau product candidate for various neurodegenerative conditions, including AD.